Nicolas BazanInhibitors of Cox-2 or Adhesion Molecules
New Targets in Inflammation
Inhibitors of Cox-2 or Adhesion Molecules
Herausgeber: Bazan, N.; Vane, John R; Botting, Jack H
Nicolas BazanInhibitors of Cox-2 or Adhesion Molecules
New Targets in Inflammation
Inhibitors of Cox-2 or Adhesion Molecules
Herausgeber: Bazan, N.; Vane, John R; Botting, Jack H
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This volume contains the proceedings of the William Harvey Research Conference held in New Orleans on the 15th and 16th of April 1996. It reviews the general pathophysiological significance of the isoforms of cyclooxygenase and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. The volume also covers the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions.
Andere Kunden interessierten sich auch für
- Membrane Transporters as Drug Targets139,99 €
- Luis M BotanaTherapeutic Targets169,99 €
- Universita Di VeronaSide-Effects of Anti-Inflammatory Drugs205,99 €
- Ion Channels as Marine Drug Targets50,99 €
- New Targets in Inflammation77,99 €
- Coronaviruses and other Novel Antiviral Targets115,99 €
- The Carbonic Anhydrases: Current and Emerging Therapeutic Targets104,99 €
-
-
-
This volume contains the proceedings of the William Harvey Research Conference held in New Orleans on the 15th and 16th of April 1996. It reviews the general pathophysiological significance of the isoforms of cyclooxygenase and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. The volume also covers the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions.
Produktdetails
- Produktdetails
- Verlag: Springer Nature
- Seitenzahl: 164
- Erscheinungstermin: 31. Dezember 1996
- Englisch
- Abmessung: 241mm x 160mm x 15mm
- Gewicht: 418g
- ISBN-13: 9780792387145
- ISBN-10: 0792387147
- Artikelnr.: 24464900
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Springer Nature
- Seitenzahl: 164
- Erscheinungstermin: 31. Dezember 1996
- Englisch
- Abmessung: 241mm x 160mm x 15mm
- Gewicht: 418g
- ISBN-13: 9780792387145
- ISBN-10: 0792387147
- Artikelnr.: 24464900
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.
Preface. 1. The History of Anti
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.
Preface. 1. The History of Anti
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.